From: The prognostic value of schizontaemia in imported Plasmodium falciparum malaria
 | All patients | Schizontaemia | No schizontaemia | P value |
---|---|---|---|---|
 | n = 401 | n = 49 | n = 352 |  |
Demographic s | Â | Â | Â | Â |
 Age, years | 39 (4–78) | 41 (4–70) | 39 (5–78) | NS |
 Male, female, n (%) | 292 (72.8), 109 (27.2) | 26 (53.1), 23 (46.9) | 266 (75.6), 86 (24.4) | 0.0018 |
Continent of acquisition | Â | Â | Â | Â |
 Africa, n (%) | 360 (89.8) | 38 (77.6) | 322 (91.5) | 0.0196 |
 Asia, n (%) | 16 (4.0) | 5 (10.2) | 11 (3.1) |  |
 South and Central America, n (%) | 10 (2.5) | 3 (6.1) | 7 (2.0) |  |
 Unknown, n (%) | 15 (3.7) | 3 (6.1) | 12 (3.4) |  |
Duration of signs/symptoms | Â | Â | Â | Â |
 <8 days, n (%) | 259 (64.6) | 30 (61.2) | 229 (65.1) | NS |
 8-14 days, n (%) | 74 (18.5) | 15 (30.6) | 59 (16.8) |  |
 15-28 days, n (%) | 27 (6.7) | 0 (0) | 27 (7.7) |  |
 >28 days, n (%) | 8 (2.0) | 0 (0) | 8 (2.3) |  |
 Unknown, n (%) | 33 (8.2) | 4 (8.2) | 29 (8.2) |  |
Use of malaria chemoprophylaxis | Â | Â | Â | Â |
 No chemoprophylaxis, n (%) | 272 (67.8) | 35 (71.4) | 237 (67.3) | NS |
 Inadequate use, n (%) | 72 (18.0) | 6 (12.2) | 66 (18.8) |  |
 Adequate use, n (%) | 39 (9.7) | 6 (12.2) | 33 (9.4) |  |
 Unknown, n (%) | 18 (4.5) | 2 (4.1) | 16 (4.5) |  |
Vital signs on admission | Â | Â | Â | Â |
 Body temperature, °C | 38.5 (35.5-41.2) | 38.7 (35.7-41.2) | 38.5 (35.5-41.0) | NS |
 Pulse rate, beats per minute | 95 (45–150) | 105 (68–150) | 92 (45–150) | 0.0002 |
 Systolic blood pressure, mm Hg | 120 (64–190) | 118 (64–160) | 120 (73–190) | NS |
 Impaired consciousness (GCS < 15), n (%) | 9 (2.2) | 5 (10.2) | 4 (1.1) | 0.0019 |
 Cerebral malaria (GCS ≤ 11), n (%) | 5 (1.2) | 2 (4.1) | 3 (0.9) | NS |
Laboratory data on admission | Â | Â | Â | Â |
 Haemoglobin, mmol/L | 8.3 (2.5-11.1) | 7.8 (3.8-10.9) | 8.4 (2.5-11.1) | NS |
 Leucocyte count, x 109/L | 5.1 (1.3-18.5) | 6.1 (2.5-18.5) | 5.0 (1.3-13.4) | 0.011 |
 Thrombocytes, x 109/L | 86 (2–385) | 38 (10–164) | 94 (2–385) | <0.0001 |
 C-reactive protein, mg/L | 98 (5–476) | 166 (22–476) | 87 (5–373) | <0.0001 |
 Serum creatinine, μmol/L | 95 (39–1,081) | 110 (39–1,081) | 95 (47–871) | 0.0019 |
 Serum sodium, mmol/L | 135 (115–146) | 132 (115–142) | 135 (119–146) | <0.0001 |
 Lactate dehydrogenase, U/L | 275 (118–2,297) | 435 (135–2,038) | 262 (118–2,297) | <0.0001 |
 Total bilirubin, μmol/L | 24 (4–416) | 44 (9–269) | 23 (4–416) | <0.0001 |
 Plasma lactate, mmol/L | 1.6 (0.5-6.2) | 2.7 (0.6-6.2) | 1.5 (0.5-4.7) | <0.0001 |
Parasite count | Â | Â | Â | Â |
 P. falciparum load (asexual parasites/μL) | 8,400 (2–1,380,600) | 162,000 (144–1,380,600) | 5,430 (2–860,000) | <0.0001 |
 Gametocytes, presence, absence, n (%) | 64 (16.0), 337 (84.0) | 11 (22.4), 38 (77.6) | 53 (15.1), 299 (84.9) | NS |